The absolute number of TRP-2_180-188–specific CD8⁺T cells generated by CpG-containing vaccines plus IL-2 did not differ between mice that underwent BMT and mice that did not undergo BMT. On day 0, age-matched thymectomized mice underwent BMT or did not undergo BMT. Both groups of mice were injected with B16F1 on day 14. Starting on day 14, the vaccination regimen described in Figure 2A that consisted of TRP-2_180-188 + CpG + IFA vaccines and systemic IL-2 was administered to both the BMT group and the non-BMT group. On day 33, the mice were killed, T cells were enumerated, and TRP-2_180-188–specific CD8⁺ T-cell responses were measured by ICCS assay as described in Figure 2. (A) Mice that underwent BMT had a smaller number of splenic CD3⁺ T cells than mice that did not undergo BMT. (B) CD3⁺CD8⁺ T cells made up a larger fraction of total CD3⁺ T cells in mice that underwent BMT than in mice that did not undergo BMT. (C) The percentages of CD8⁺ T cells that were TRP-2_180-188–specific in mice that underwent BMT and in mice that did not undergo BMT are shown. (D) The absolute number of TRP-2_180-188–specific CD8⁺ T cells was equivalent in mice that underwent BMT and mice that did not undergo BMT. The data described in (A)-(D) were obtained from the same mice (n = 8 mice per group). (E) The B16F1 tumor growth rate was equivalent in mice that underwent BMT and mice that did not undergo BMT (n = 12 mice per group).